Fig 1: An overview of the main molecular, cellular and signaling functions of SLAMF7 as regards its involvement in the immune system, as well as in other tissues. SLAMF7, signaling lymphocytic activation molecule F7.
Fig 2: Cytoplasmic expression patterns of signaling lymphocytic activation molecule F7 in primary BC tissues, as shown using immunohistochemical staining. (A) Negative (0) cytoplasmic expression, (B) weak (1+) cytoplasmic expression, (C) moderate (2+) cytoplasmic expression, (D) strong (3+) cytoplasmic expression, (E) distribution of low (0, 1+) vs. high (2+, 3+) protein expression of SLAMF7 among primary BC tissues of the studied cohort. BC, breast cancer.
Fig 3: Cytoplasmic SLAMF7 expression patterns in the primary lymph node-positive breast cancer cohort using the cut-off [negative (0) vs. positive (1+, 2+ and 3+)] as a determinant of disease-specific survival in univariate (Kaplan-Meier) analysis (P<0.008, log-rank test). SLAMF7, signaling lymphocytic activation molecule F7.
Fig 4: Cytoplasmic SLAMF7 expression patterns in the primary lymph node-positive breast cancer cohort using the cut-off [negative (0) vs. positive (1+, 2+ and 3+)] as a determinant of disease-free survival in univariate (Kaplan-Meier) analysis (P<0.001, log-rank test). SLAMF7, signaling lymphocytic activation molecule F7.
Fig 5: (A) Motif analysis showing a significant enrichment of multiple TF motifs in UV-induced DHA regions in keratinocytes following UVR; (B) RNA-seq results showing mRNA expression changes of the TFs identified in Fig. 4A between UV-irradiated and control keratinocytes; (C) Loss of function of selected UV-responsive TFs is significantly more detrimental to skin cancer cells than non-skin cancer cells; (D) Loss of function of selected UV target genes in Fig. 3B (more than 2-fold increases in both DGE and DHA) is significantly more detrimental to skin cancer cells than non-skin cancer cells. P-values were obtained using the Wilcoxon test by comparing the gene depletion scores between the skin cancer cells versus the non-skin cancer cells; (E) Box plot illustrating the Log2FC in the expression of the genes shown in Fig. 4C and D among 5 pairs of SCC and normal skin tissues. SLAMF7, ARNTL, ETV1, and GPR115 show more consistent upregulation in SCCs.
Supplier Page from Abcam for Anti-SLAMF7/CS1 antibody